FDA Issues New Safety Alert on Reumofan
The Food and Drug Administration (FDA) issued a new warning to consumers about the potential health risks of two products marketed as natural dietary supplements for treating arthritis, muscle pain, osteoporosis, bone cancer, and other conditions. The FDA says it has received dozens of additional adverse event reports of bleeding, stroke, liver damage and death among users of Reumofan Plus and Reumofan